CytomX Reconciled Depreciation vs Operating Income Analysis
CTMX Stock | USD 1.89 0.11 5.50% |
CytomX Therapeutics financial indicator trend analysis is way more than just evaluating CytomX Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CytomX Therapeutics is a good investment. Please check the relationship between CytomX Therapeutics Reconciled Depreciation and its Operating Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.
Reconciled Depreciation vs Operating Income
Reconciled Depreciation vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CytomX Therapeutics Reconciled Depreciation account and Operating Income. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between CytomX Therapeutics' Reconciled Depreciation and Operating Income is -0.48. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Operating Income in the same time period over historical financial statements of CytomX Therapeutics, assuming nothing else is changed. The correlation between historical values of CytomX Therapeutics' Reconciled Depreciation and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of CytomX Therapeutics are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Reconciled Depreciation i.e., CytomX Therapeutics' Reconciled Depreciation and Operating Income go up and down completely randomly.
Correlation Coefficient | -0.48 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Reconciled Depreciation
Operating Income
Operating Income is the amount of profit realized from CytomX Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of CytomX Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from CytomX Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.Tax Provision is likely to rise to about 3 M in 2024, whereas Selling General Administrative is likely to drop slightly above 28.8 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 69.6M | 53.2M | 99.0M | 53.9M | Total Revenue | 69.6M | 53.2M | 101.2M | 54.2M |
CytomX Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
CytomX Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CytomX Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 341.3M | 358.7M | 339.4M | 260.9M | 205.2M | 284.4M | |
Other Current Liab | 27.2M | 19.9M | 30.6M | 24.5M | 17.6M | 17.9M | |
Total Current Liabilities | 85.6M | 100.9M | 106.3M | 152.6M | 155.9M | 82.7M | |
Total Stockholder Equity | 51.1M | 49.8M | 89.4M | (85.8M) | (47.4M) | (45.1M) | |
Other Liab | 179.7M | 186.3M | 125.7M | 180.1M | 207.1M | 151.2M | |
Property Plant And Equipment Net | 32.8M | 29.4M | 25.3M | 21.0M | 16.2M | 14.9M | |
Current Deferred Revenue | 51.4M | 74.9M | 69.3M | 121.3M | 132.3M | 138.9M | |
Net Debt | (163.6M) | (167.0M) | (187.5M) | (175.6M) | (3.2M) | (3.4M) | |
Retained Earnings | (417.2M) | (450.1M) | (533.7M) | (722.9M) | (723.4M) | (687.3M) | |
Accounts Payable | 4.2M | 3.0M | 2.8M | 2.8M | 1.5M | 2.7M | |
Cash | 188.4M | 191.9M | 205.5M | 193.7M | 17.2M | 16.3M | |
Non Current Assets Total | 37.9M | 34.7M | 29.1M | 23.8M | 22.2M | 19.8M | |
Non Currrent Assets Other | 2.9M | (3.4M) | (3.7M) | (3.6M) | 83K | 78.9K | |
Other Assets | 2.9M | 25.6M | 1.8M | 944K | 1.1M | 1.0M | |
Cash And Short Term Investments | 296.1M | 316.1M | 305.2M | 193.7M | 174.5M | 253.8M | |
Net Receivables | 13K | 798K | 790K | 36.0M | 3.4M | 5.6M | |
Common Stock Shares Outstanding | 45.3M | 46.1M | 64.1M | 65.7M | 73.8M | 48.9M | |
Short Term Investments | 188.6M | 107.7M | 124.3M | 99.7M | 157.3M | 117.8M | |
Liabilities And Stockholders Equity | 341.3M | 358.7M | 339.4M | 260.9M | 205.2M | 284.4M | |
Non Current Liabilities Total | 204.6M | 207.9M | 143.7M | 194.0M | 96.7M | 167.7M | |
Other Current Assets | 7.2M | 7.1M | 4.3M | 7.5M | 5.0M | 5.2M | |
Other Stockholder Equity | 468.3M | 500.0M | 623.3M | 637.1M | 675.9M | 709.7M | |
Total Liab | 290.2M | 308.9M | 250.0M | 346.6M | 252.6M | 250.4M | |
Property Plant And Equipment Gross | 32.8M | 29.4M | 25.3M | 21.0M | 30.9M | 16.4M | |
Total Current Assets | 303.3M | 324.0M | 310.3M | 237.1M | 182.9M | 264.6M | |
Accumulated Other Comprehensive Income | 57K | (47K) | (242K) | 10K | 95K | 99.8K | |
Short Term Debt | 2.8M | 3.2M | 3.6M | 4.1M | 4.6M | 4.7M | |
Intangible Assets | 1.3M | 1.2M | 1.0M | 875K | 729K | 1.1M | |
Property Plant Equipment | 6.9M | 32.8M | 7.0M | 6.0M | 6.9M | 8.3M | |
Net Tangible Assets | 48.9M | 47.7M | 87.4M | (2.4M) | (2.8M) | (2.7M) | |
Retained Earnings Total Equity | (417.2M) | (450.1M) | (533.7M) | (623.6M) | (561.2M) | (533.1M) | |
Capital Surpluse | 446.0M | 468.3M | 500.0M | 623.3M | 716.8M | 474.2M | |
Non Current Liabilities Other | 850K | 207.9M | 143.7M | 262M | 3.9M | 3.7M | |
Net Invested Capital | 51.1M | 49.8M | 89.4M | (85.8M) | (47.4M) | (45.1M) | |
Net Working Capital | 217.7M | 223.1M | 204.0M | 84.5M | 27.0M | 25.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for CytomX Stock analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.21 | Revenue Per Share 1.533 | Quarterly Revenue Growth 0.764 | Return On Assets 0.0323 | Return On Equity (54.75) |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.